2nd Quarter - Report

APOTEX CORP. for APOTEX CORP.

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Legislation concerning reimbursement for generic drugs under the Medicaid program

Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

S. 515, the Patent Reform Act of 2009 concerning inenquitable conduct

Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 515 (111th)

Pharmacy PHA

S. 369, the Preserve Access to Affordable Pharmaceuticals Act HR 1706, the Protecting Consumer Access to Generic Drugs Act HR 1427, the Promoting Innovation and Access to Life Saving Medicine Act S. 726, the Promoting Innovation and Access to Life Saving Medicine Act HR 1548, Pathway for Biosimilars Act S. 501, the Fair Prescription Drug Competition Act S. 767, the Independent Drug Education and Outreach Act S. 1315, the Price Competition Act of 2009 HR 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010, Title VI, FDA, concerning funding for the Office of Generic Drugs Electronic labeling for pharmaceuticals

Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.

LobbyistCovered position, as disclosed
STEVEN GIULI —

Contacted: Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2997 (111th), H.R. 1548 (111th), H.R. 1427 (111th), S. 726 (111th), S. 1315 (111th), S. 767 (111th), S. 501 (111th), H.R. 1706 (111th), S. 369 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.